The_DT
DNA_NN
binding_NN
domain_NN
of_IN
the_DT
A-MYB_NN
transcription_NN
factor_NN
is_VBZ
responsible_JJ
for_IN
its_PRP$
B_NN
cell-specific_JJ
activity_NN
and_CC
binds_VBZ
to_TO
a_DT
B_NN
cell_NN
110-kDa_JJ
nuclear_JJ
protein_NN
._.

Expression_NN
studies_NNS
as_RB
well_RB
as_IN
the_DT
use_NN
of_IN
transgenic_JJ
animals_NNS
have_VBP
demonstrated_VBN
that_IN
the_DT
A-MYB_NN
transcription_NN
factor_NN
plays_VBZ
central_JJ
and_CC
specific_JJ
role_NN
in_IN
the_DT
regulation_NN
of_IN
mature_JJ
B_NN
cell_NN
proliferation_NN
and\/or_CC
differentiation_NN
._.

Furthermore_RB
,_,
it_PRP
is_VBZ
highly_RB
expressed_VBN
in_IN
Burkitt_NN
's_POS
lymphoma_NN
cells_NNS
and_CC
may_MD
participate_VB
in_IN
the_DT
pathogenesis_NN
of_IN
this_DT
disease_NN
._.

We_PRP
have_VBP
therefore_RB
investigated_VBN
the_DT
transcriptional_JJ
activity_NN
of_IN
A-MYB_NN
and_CC
its_PRP$
regulation_NN
in_IN
several_JJ
human_JJ
lymphoid_JJ
cell_NN
lines_NNS
using_VBG
co-transfection_NN
assays_NNS
and_CC
show_VBP
that_IN
A-MYB_NN
is_VBZ
transcriptionally_RB
active_JJ
in_IN
all_PDT
the_DT
B_NN
cell_NN
lines_NNS
studied_VBN
,_,
but_CC
not_RB
in_IN
T_NN
cells_NNS
._.

In_IN
particular_JJ
the_DT
best_JJS
responder_NN
cell_NN
line_NN
was_VBD
the_DT
Burkitt_NN
's_POS
cell_NN
line_NN
Namalwa_NN
._.

The_DT
activity_NN
of_IN
A-MYB_NN
in_IN
B_NN
and_CC
not_RB
T_NN
cells_NNS
was_VBD
observed_VBN
when_WRB
either_CC
an_DT
artificial_JJ
construct_NN
or_CC
the_DT
c-MYC_NN
promoter_NN
was_VBD
used_VBN
as_IN
a_DT
reporter_NN
._.

Furthermore_RB
,_,
the_DT
functional_JJ
domains_NNS
responsible_JJ
for_IN
DNA_NN
binding_NN
,_,
transactivation_NN
,_,
and_CC
negative_JJ
regulation_NN
,_,
previously_RB
characterized_VBN
in_IN
a_DT
fibroblast_NN
context_NN
,_,
were_VBD
found_VBN
to_TO
have_VB
similar_JJ
activity_NN
in_IN
B_NN
cells_NNS
._.

The_DT
region_NN
of_IN
A-MYB_NN
responsible_JJ
for_IN
the_DT
B_NN
cell_NN
specific_JJ
activity_NN
was_VBD
defined_VBN
to_TO
be_VB
the_DT
N-terminal_JJ
218_CD
amino_NN
acids_NNS
containing_VBG
the_DT
DNA_NN
binding_NN
domain_NN
._.

Finally_RB
,_,
a_DT
110-kDa_JJ
protein_NN
has_VBZ
been_VBN
identified_VBN
in_IN
the_DT
nuclei_NNS
of_IN
all_PDT
the_DT
B_NN
,_,
but_CC
not_RB
T_NN
,_,
cell_NN
lines_NNS
that_WDT
specifically_RB
binds_VBZ
to_TO
this_DT
A-MYB_NN
N-terminal_JJ
domain_NN
._.

We_PRP
hypothesize_VBP
that_IN
this_DT
110-kDa_JJ
protein_NN
may_MD
be_VB
a_DT
functionally_RB
important_JJ
B_NN
cell-specific_JJ
co-activator_NN
of_IN
A-MYB_NN
._.

